
|Articles|April 1, 2004
Levofloxacin 1.5% earns FDA approval
Minneapolis, MN-The new fluoroquinolone, levofloxacin 1.5% ophthalmic solution (IQUIX, Santen), has received FDA approval to be marketed for the treatment of bacterial corneal ulcer. The approval brings with it a milestone as the first current-generation fluoroquinolone with an indication for use in the management of that sight-threatening condition, explained Richard L. Lindstrom, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
3
Throwback Series: Managing bilateral diabetic macular edema early in practice
4
ICYMI: AAO 2025 showcases new technologies and continued research
5

















































.png)


